Neuronetics (NASDAQ:STIM) posted its quarterly earnings results on Tuesday. The company reported ($0.37) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.41) by $0.04, Fidelity Earnings reports. Neuronetics had a negative net margin of 45.35% and a negative return on equity of 42.24%. The company had revenue of $16.00 million during the quarter, compared to analyst estimates of $16.13 million.
NASDAQ STIM traded down $0.20 during trading on Friday, hitting $4.90. The company had a trading volume of 234,600 shares, compared to its average volume of 78,138. The company has a current ratio of 6.10, a quick ratio of 5.95 and a debt-to-equity ratio of 0.51. The company has a market cap of $100.93 million, a price-to-earnings ratio of -1.82 and a beta of 0.98. The company’s fifty day moving average is $8.84 and its 200-day moving average is $11.42. Neuronetics has a one year low of $4.81 and a one year high of $27.34.
STIM has been the subject of a number of recent analyst reports. Zacks Investment Research upgraded shares of Neuronetics from a “hold” rating to a “buy” rating and set a $5.75 price target for the company in a report on Friday. JMP Securities decreased their price objective on shares of Neuronetics from $40.00 to $12.00 and set a “market outperform” rating for the company in a report on Wednesday. ValuEngine lowered shares of Neuronetics from a “buy” rating to a “hold” rating in a report on Tuesday. Finally, BTIG Research decreased their price objective on shares of Neuronetics to $11.00 and set an “average” rating for the company in a report on Wednesday. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Neuronetics currently has an average rating of “Buy” and an average target price of $14.19.
In other Neuronetics news, CEO Christopher Thatcher sold 20,000 shares of the company’s stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $10.74, for a total transaction of $214,800.00. 12.00% of the stock is currently owned by corporate insiders.
Neuronetics Company Profile
Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States, Japan, and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.
Featured Story: Why is the price target of stocks important?
Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.